IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy

Radiotherapy and Oncology

Volumn 93, Issue 2, 2009, Pages 207-212

  Alongi, Filippo ^a,b,c   Fiorino, Claudio ^a   Cozzarini, Cesare ^a   Broggi, Sara ^a   Perna, Lucia ^a   Cattaneo, Giovanni Mauro ^a   Calandrino, Riccardo ^a   Di Muzio, Nadia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Institute of Molecular Bioimaging and Physiology   (Italy)

^c LATO HSR G Giglio   (Italy)

Author keywords

Acute toxicity; IMRT; Post operative; Whole pelvis irradiation

Indexed keywords

BICALUTAMIDE; GONADORELIN ANTAGONIST;

ACUTE TOXICITY; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION INJURY; RETROSPECTIVE STUDY; RISK REDUCTION; SALVAGE THERAPY; TOMOTHERAPY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

AGED; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; PELVIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; UROGENITAL SYSTEM;

EID: 70350746418     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.08.042     Document Type: Article

References (40)

1. Roach M., DeSilvio C., Lawton C.A., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neo-adjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
2. Spiotto M.T., Hancock S.L., and King C.R. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69 (2007) 54-61
3. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. A multi-institutional update. J Am Med Assoc 277 (1997) 1445-1451
4. Roach M., Marquez C., You H., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localised prostate cancer. Int J Radiat Oncol Biol Phys 28 (1993) 33-37
5. Stone N.N., Stock R.G., and Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 158 (1997) 18-94
6. Heidenreich A., Varga Z., and Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167 (2002) 1681-1686
7. Wagner M. The role of pelvic lymphadenectomy for prostate cancer: therapeutic?. J Urol 179 (2008) 408-413
8. Herold D.M., Hanlon A.L., and Hanks G.E. Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 43 (1999) 475-479
9. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
10. Fiorino C., Alongi F., Broggi S., et al. Physics aspects of prostate tomotherapy: planning optimization and image-guidance issues. Acta Oncol 47 (2008) 1309-1316
11. Cozzarini C., Bolognesi A., Ceresoli G.L., et al. Role of post-operative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys 59 (2004) 674-683
12. Poortmans P., Bossi A., Vandeputte K., et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 84 (2007) 121-127
13. Martinez-Monge R., Fernandes P.S., Gupta N., and Gahbauer R. Cross-sectional nodal atlas: a tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology 211 (1999) 815-828
14. Fokdal L., Honore H., Hoyer M., and Von der M. Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. Radiother Oncol 74 (2005) 203-210
15. Hysing L.B., Kvinnsland Y., Lord H., and Muren L.P. Planning organ at risk volume margins for organ motion of the intestine. Radiother Oncol 80 (2006) 349-354
16. Sanguineti G., Little M., Endres E.J., et al. Comparison of three strategies to delineate the bowel for whole-pelvis IMRT of prostate cancer. Radiother Oncol 88 (2008) 95-101
17. Kvinnsland Y., and Muren L.P. The impact of organ motion on intestine doses and complication probabilities in radiotherapy of bladder cancer. Radiother Oncol 76 (2005) 43-47
18. Hysing L.B., Skorpen T.N., Alber M., et al. Influence of organ motion of conformal vs. intensity-modulated pelvic radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 71 (2008) 1496-1503
19. Fiorino C., Alongi F., Perna L., et al. Dose-volume relationships for acute bowel toxicity for patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 75 (2009) 29-35
20. Cavey M.L., Bayouth J.E., Colman M., et al. IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlenther Onkol 181 (2005) 431-441
21. Price R.A.J., Hannoun-Levi J.M., Horwitz E., et al. Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 583-592
22. Sanguineti G., Cavey M.L., Endres E.J., et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?. Strahlenther Onkol 182 (2006) 543-549
23. Fiorino C., Sanguineti G., Cozzarini C., et al. Dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57 (2003) 953-962
24. Rancati T., Fiorino C., Gagliardi G., et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 73 (2004) 21-32
25. Fiorino C., Cozzarini C., Vavassori V., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
26. Bolla M., van Poppel H., and Collette L. Post-operative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
27. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
28. Morgan S.C., Waldron T.S., Eapen L., et al. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol. 88 (2008) 1-9
29. Cozzarini C., Fiorino C., Di Muzio N., et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol 8 (2007) 164-170
30. Arcangeli S., Saracino B., Petrongari M.G., et al. Analysis of toxicity in patients with high-risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 84 (2007) 148-155
31. Di Muzio N., Fiorino C., Cozzarini C., et al. Phase I-II study of hipofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1 (2009) 392-398
32. Sanguineti G., Endres E.J., Parker B.C., et al. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. Acta Oncol 47 (2008) 301-310
33. Pasquier D., and Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys 72 (2008) 972-979
34. Jereczek-Fossa B.A., Zerini D., Vavassori A., et al. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with post-operative or salvage radiotherapy. Int J Radiat Oncol Biol Phys 74 (2009) 115-125
35. Van Der Poel H.G., Moonen L., and Horenblas S. Sequential treatment for recurrent localized prostate cancer. J Surg Oncol 97 (2008) 377-382
36. Eulau S.M., Tate D.J., Stamey T.A., Bagshaw M.A., and Hancock S.L. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 41 (1998) 735-740
37. King C.R., Presti J.C.J., Gill H., Brooks J., and Hancock S.L. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys 59 (2004) 341-347
38. Peeters S.T., Hoogeman M.S., Heemsbergen W.D., et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 15 (2005) 1142-1152
39. King C.R., and Kapp D.S. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys 71 (2008) 346-350
40. Cozzarini C, Montorsi F, Fiorino C, et al. The need for high radiation doses (≥70 Gy) even in early post-operative irradiation after radical prostatectomy. A mono-institutional analysis on 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 2009; doi:10.1016/j.ijrobp.2008.12.059.